Is the FDA Finally Cleaning House? A Veteran Takes the Helm Amid Scandal and Suits

FDA终于要整顿门户了？老将临危受命，丑闻与诉讼风暴中接过帅印

So the FDA has replaced its embattled drug chief with Richard Pazdur—yes, that Pazdur, the oncology czar who’s been quietly revolutionizing cancer drug approvals for years. George Tidmarsh is out after barely a month, ousted by allegations of personal vendettas and a lawsuit from Aurinia Pharmaceuticals. If this were a TV drama, we’d call it ‘The Fall of the CDER Emperor.’

于是FDA把陷入困境的药物主管换成了理查德·帕兹多——没错，就是那位多年来默默革新癌症药物审批的肿瘤学沙皇。乔治·蒂德马什上任不到一个月就被扫地出门，原因是指控他因私人恩怨滥用职权，还被Aurinia制药公司起诉。如果这是部美剧，我们大概会叫它《CDER帝国的陨落》。

Pazdur’s appointment is being framed as a return to integrity, science, and stability. But let’s be honest—does installing a beloved bureaucrat really fix a system where regulators can allegedly target companies out of petty grudges? And isn’t it wild that the guy reportedly said no twice before finally taking the job? Sounds less like a promotion and more like a hostage rescue.

帕兹多的任命被描绘为回归诚信、科学与稳定。但我们实话实说——派一位受人爱戴的官僚上任，真能修复一个监管者据说会因小恩怨打击药企的体系吗？更离谱的是，据说他连续两次拒绝，最后才勉强接手。这哪是升职，简直像被绑走救人质。

Pharma Insider (药企内部人)

Pazdur’s track record in oncology approvals is stellar. He pushed for accelerated pathways based on real patient outcomes, not just bureaucratic checkboxes. If he applies that mentality to the entire CDER, it could finally break the logjam on innovative drugs.

帕兹多在肿瘤药审批上的记录堪称卓越。他推动基于真实患者疗效的加速通道，而非官僚形式主义。如果他把这种理念推广到整个CDER，或许真能打破创新药物审批的僵局。

Health Policy Skeptic (医疗政策怀疑论者)

Don't get me wrong—Pazdur’s a legend. But heroes don’t fix broken systems. The real issue is structural: lack of oversight, political interference, and revolving doors. This is a Band-Aid on a hemorrhage.

别误会——帕兹多确实是传奇。但英雄救不了烂体制。真正问题是结构性的：缺乏监督、政治干预、政商旋转门。这不过是给大出血贴了个创可贴。

Litigation Hawk (诉讼猎手)

Let’s talk about the lawsuit. Aurinia’s filing says Tidmarsh smeared their drug out of a vendetta against the CEO. That’s not overreach—that’s a career-ending, jail-worthy abuse of authority.

说说那场诉讼。Aurinia的诉状称蒂德马什因与CEO有私怨，故意抹黑他们的药。这已不仅是越权——这是足以断送职业生涯、甚至坐牢的权力滥用。

Public Health Realist (公共卫生务实派)

Bottom line: patients need drugs faster, but not at the cost of safety. Pazdur walks the tightrope better than most. He approves fast but demands real evidence. That balance is rare.

根本问题：患者需要更快的药物，但不能以牺牲安全为代价。帕兹多比大多数人更擅长走钢丝——他批准得快，但仍要求真实证据。这种平衡极为罕见。

Sarcastic Med Student (毒舌医学生)

Of course the FDA’s savior is a cancer guy. Because nothing says ‘systemic reform’ like focusing only on the diseases with PR budgets.

FDA的救世主当然得是搞癌症的。毕竟，还有什么比只关注有公关预算的疾病，更能体现‘系统性改革’呢？

Regulatory Watchdog (监管哨兵)

You think the problem is optics? The fact that a respected figure only took the job after two refusals? That’s not optics—that’s a flashing red alarm that no one sane wants this poisoned chalice.

你觉得问题只是形象？一位受尊敬的人物拒绝两次才上任？这已不只是形象问题——这是刺眼的红色警报：没哪个理智的人会想要这个毒杯。

Patient Advocate (患者权益倡导者)

I don’t care about the drama. I care that my kid gets access to treatments that work. If Pazdur speeds things up without cutting corners, I’ll take the drama. Every day counts.

我才不在乎这些闹剧。我在乎的是我的孩子能用上真正有效的治疗。如果帕兹多能在不偷工减料的前提下加快审批，那我愿意接受这些纷争。每一天都很重要。

Former FDA Intern (前FDA实习生)

Worked at CDER for six months. Culture is broken. Managers play politics. Scientists feel ignored. Pazdur’s style? He actually listens. Small thing, huge difference.

在CDER实习过半年。文化早已崩坏：管理层搞政治，科学家被无视。帕兹多的风格？他会认真倾听。小事一件，却天差地别。

Is the FDA Finally Cleaning House? A Veteran Takes the Helm Amid Scandal and Suits

FDA终于要整顿门户了？老将临危受命，丑闻与诉讼风暴中接过帅印

终于摆脱药物恐慌？FDA撤销更年期激素疗法的黑框警告

领导力缺失正在毁掉我们的国民医疗系统吗？揭开中埃塞克斯和南埃塞克斯医院危机背后的惊人真相